The combination of dexamethasone, high-dose cytarabine, and cisplatin (DHAP) is used as salvage chemotherapy for relapsed or refractory lymphoma. It includes the administration of cisplatin in a single dose of 100 mg/m2, and renal toxicity is a common adverse event. In this study, we retrospectively analyzed the risk factors for renal toxicity (≥ grade 2) in 74 patients who received DHAP as salvage chemotherapy. Regarding maximal renal toxicities, 38 (51.4%), 6 (8.1%), and 1 (1.4%) patients had grade 2, 3, and 4 toxicities, respectively. Multivariate analyses revealed that overweight (body mass index ≥ 25) was an independent predictive factor for renal toxicity of ≥ grade 2 (odds ratio [OR] 4.08, P = 0.032). A subgroup analysis for patients with diffuse large B cell lymphoma treated with DHAP as second-line therapy (n = 44) confirmed that overweight was an independent risk factor (OR 5.28, P = 0.049). In conclusion, we demonstrated that overweight was an independent risk factor for renal toxicity of ≥ grade 2 in patients who received DHAP. Further clinical studies will be needed to identify a method to decrease renal toxicities after the administration of cisplatin.

中文翻译：

---

超重对地塞米松，大剂量阿糖胞苷和顺铂治疗的患者肾毒性的影响。

地塞米松，大剂量阿糖胞苷和顺铂（DHAP）的组合可用于复发性或难治性淋巴瘤的挽救性化疗。它包括以100 mg / m2的单剂量施用顺铂，肾脏毒性是常见的不良事件。在这项研究中，我们回顾性分析了74名接受DHAP进行挽救性化疗的患者发生肾毒性（≥2级）的危险因素。在最大肾脏毒性方面，分别有38（51.4％），6（8.1％）和1（1.4％）的患者分别具有2、3和4级毒性。多变量分析显示，超重（体重指数≥25）是≥2级肾毒性的独立预测因素（比值比[OR]为4.08，P = 0.032）。对以DHAP作为二线治疗的弥漫性大B细胞淋巴瘤患者进行亚组分析（n = 44），证实超重是一个独立的危险因素（OR 5.28，P = 0.049）。总之，我们证明，超重是接受DHAP的患者≥2级肾毒性的独立危险因素。需要进一步的临床研究，以确定减少顺铂给药后肾毒性的方法。